Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by guildwood1on Mar 02, 2015 2:06pm

137 Views

Post# 23480804

RE:RE:RE:RE:RE:RE:RE:RE:Director Resignation

A bit excessive much? No poster has any legal liability for anyone's actions resulting in a loss. All these forms are for information sharing and opinion and if you choose to invest based on others opinions that's your discretion and thus are solely responsible for your own actions. How about back to business as opposed to blatant scare tactics on exaggerated opinions.

Bullboard Posts

Visionstate set to leverage success in the U.S. market